Call for participating: MF Ruxolitinib
Chronic Malignancies Working Party studyWe would like to invite you to participate in a retrospective study of the Chronic Malignancies Working Party regarding the effect of pretreatment with JAK inhibitor ruxolitinib in patients with primary or post ET/PV myelofibrosis on outcome after allogeneic HSCT.
For this study we seek to include MF patients with and without such prior treatment.
In this retrospective EBMT registry study the impact of ruxolitinib treatment prior to allogeneic HSCT on outcome such as engraftment, graft–versus-host disease, non-relapse mortality, relapse and overall survival will be addressed and compared to patients who received - in the same time period - allogeneic HSCT without ruxolitinib pretreatment.
Inclusion criteria for this study are:
If you are interested in this study, please contact Linda Koster: email@example.com
A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.Study design: Open label randomised clinical trial
Primary objective: To investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated aplastic anemia patients.
Status: July 12, 2018